​

ResMed (RMD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RMD Stock Forecast

ResMed (RMD) stock forecast, based on 28 Wall Street analysts, predicts a 12-month average price target of $255.00, with a high of $265.00 and a low of $240.00. This represents a 19.77% increase from the last price of $212.91.

$170 $189 $208 $227 $246 $265 High: $265 Avg: $255 Low: $240 Last Closed Price: $212.91

RMD Stock Rating

ResMed stock's rating consensus is Buy, based on 28 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (53.57%), 12 Hold (42.86%), 1 Sell (3.57%), and 0 Strong Sell (0.00%).

Buy
Total 28 1 12 15 Strong Sell Sell Hold Buy Strong Buy

RMD Price Target Upside V Benchmarks

TypeNameUpside
StockResMed19.77%
SectorHealthcare Stocks 35.25%
IndustryMedical Instruments & Supplies Stocks34.02%

Price Target Trends

1M3M12M
# Anlaysts137
Avg Price Target$265.00$255.00$242.71
Last Closing Price$212.91$212.91$212.91
Upside/Downside24.47%19.77%14.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 254861-19
Mar, 253771-18
Feb, 252781-18
Jan, 253681-18
Dec, 243671-17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 16, 2025Anthony PetroneMizuho Securities$265.00$211.4925.30%24.47%
Mar 05, 2025Stifel Nicolaus$240.00$223.837.22%12.72%
Jan 31, 2025Adam MaederPiper Sandler$260.00$236.1810.09%22.12%
Dec 12, 2024Jonathan BlockStifel Nicolaus$250.00$242.513.09%17.42%
Oct 01, 2024Craig Wong-PanRBC Capital$224.00$238.95-6.26%5.21%
Sep 23, 2024Joe VruwinkRobert W. Baird$280.00$246.1813.74%31.51%
Sep 18, 2024Mike PolarkWolfe Research$180.00$250.88-28.25%-15.46%
Apr 10, 2024Craig Wong-PanRBC Capital$187.00$194.27-3.74%-12.17%
Apr 01, 2024Mike MatsonStifel Nicolaus$224.00$198.0313.11%5.21%
Oct 27, 2023Suraj KaliaOppenheimer$175.00$134.6529.97%-17.81%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 05, 2025CitigroupNeutralBuyupgrade
Jan 31, 2025RBC CapitalSector PerformSector Performhold
Jan 31, 2025UBSSector PerformBuyupgrade
Jan 31, 2025KeyBancOverweightOverweighthold
Jan 31, 2025Piper SandlerNeutralNeutralhold
Jan 10, 2025Piper SandlerNeutralNeutralinitialise
Oct 01, 2024RBC CapitalSector PerformSector Performhold
Sep 24, 2024Wolfe ResearchSector PerformSector Performhold
Sep 18, 2024NeedhamHoldHoldhold
Sep 18, 2024Wolfe ResearchPeer PerformUnderperformdowngrade

Financial Forecast

EPS Forecast

$0 $3 $6 $9 $12 $15 Jun 20 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 20Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$4.31$3.27$5.34$6.12$6.94-----
Avg Forecast$4.51$5.30$5.71$6.50$7.73$9.41$10.38$11.34$12.14$13.55
High Forecast$4.69$5.51$5.94$6.64$7.79$9.56$11.06$12.05$12.40$13.84
Low Forecast$4.37$5.13$5.53$6.30$7.63$9.16$9.64$10.70$11.77$13.13
Surprise %-4.43%-38.30%-6.48%-5.85%-10.22%-----

Revenue Forecast

$3B $4B $5B $6B $7B $8B Jun 20 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 20Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$2.96B$3.20B$3.58B$4.22B$4.69B-----
Avg Forecast$2.94B$3.12B$3.58B$4.24B$4.68B$5.12B$5.50B$5.89B$6.31B$6.97B
High Forecast$3.04B$3.22B$3.69B$4.31B$4.70B$5.16B$5.59B$5.90B$6.41B$7.08B
Low Forecast$2.87B$3.04B$3.49B$4.14B$4.66B$5.09B$5.26B$5.88B$6.16B$6.80B
Surprise %0.45%2.48%0.04%-0.36%0.12%-----

Net Income Forecast

$0 $500M $1B $2B $2B $3B Jun 20 Jun 21 Jun 22 Jun 23 Jun 24 Jun 25 Jun 26 Jun 27 Jun 28 Jun 29
Jun 20Jun 21Jun 22Jun 23Jun 24Jun 25Jun 26Jun 27Jun 28Jun 29
Reported$621.67M$474.50M$779.44M$897.56M$1.02B-----
Avg Forecast$411.03M$559.05M$492.41M$959.76M$1.11B$1.38B$1.48B$1.62B$1.79B$2.00B
High Forecast$493.24M$670.86M$621.54M$980.02M$1.34B$1.41B$1.63B$1.78B$1.83B$2.04B
Low Forecast$328.83M$447.24M$363.28M$929.76M$890.31M$1.35B$1.42B$1.58B$1.74B$1.94B
Surprise %51.25%-15.12%58.29%-6.48%-8.26%-----

RMD Forecast FAQ

Is ResMed stock a buy?

ResMed stock has a consensus rating of Buy, based on 28 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 12 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that ResMed is a favorable investment for most analysts.

What is ResMed's price target?

ResMed's price target, set by 28 Wall Street analysts, averages $255 over the next 12 months. The price target range spans from $240 at the low end to $265 at the high end, suggesting a potential 19.77% change from the previous closing price of $212.91.

How does ResMed stock forecast compare to its benchmarks?

ResMed's stock forecast shows a 19.77% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the medical instruments & supplies stocks industry (34.02%).

What is the breakdown of analyst ratings for ResMed over the past three months?

  • April 2025: 21.05% Strong Buy, 42.11% Buy, 31.58% Hold, 5.26% Sell, 0% Strong Sell.
  • March 2025: 16.67% Strong Buy, 38.89% Buy, 38.89% Hold, 5.56% Sell, 0% Strong Sell.
  • February 2025: 11.11% Strong Buy, 38.89% Buy, 44.44% Hold, 5.56% Sell, 0% Strong Sell.

What is ResMed’s EPS forecast?

ResMed's average annual EPS forecast for its fiscal year ending in June 2025 is $9.41, marking a 35.59% increase from the reported $6.94 in 2024. Estimates for the following years are $10.38 in 2026, $11.34 in 2027, $12.14 in 2028, and $13.55 in 2029.

What is ResMed’s revenue forecast?

ResMed's average annual revenue forecast for its fiscal year ending in June 2025 is $5.12B, reflecting a 9.29% increase from the reported $4.69B in 2024. The forecast for 2026 is $5.5B, followed by $5.89B for 2027, $6.31B for 2028, and $6.97B for 2029.

What is ResMed’s net income forecast?

ResMed's net income forecast for the fiscal year ending in June 2025 stands at $1.38B, representing an 35.31% increase from the reported $1.02B in 2024. Projections indicate $1.48B in 2026, $1.62B in 2027, $1.79B in 2028, and $2B in 2029.